Gastrointestinal Diseases
Conditions
Interventions
Ciprofol 0.2mg/kg:No drug was given before induction of anesthesia, and 5ug/kg of alfentanil was slowly injected during induction of anesthesia, followed by a slow injection of the corresponding dose
Ciprofol 0.3mg/kg:No drug was given before induction of anesthesia, and 5ug/kg of alfentanil was slowly injected during induction of anesthesia, followed by a slow injection of the corresponding dose
Ciprofol 0.4mg/kg:No drug was given before induction of anesthesia, and 5ug/kg of alfentanil was slowly injected during induction of anesthesia, followed by a slow injection of the corresponding dose
Ciprofol 0.5mg/kg:No drug was given before induction of anesthesia, and 5ug/kg of alfentanil was slowly injected during induction of anesthesia, followed by a slow injection of the corresponding dose
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1: Voluntarily undergo painless gastroscopy and sign the relevant informed consent form 2: Any gender, age = 18 years 3: American Society of Anesthesiologists (ASA) classification I-III 4: Body mass index 18.5-27kg/m2
Exclusion criteria
Exclusion criteria: 1: Hypersensitivity to drugs used in this study or contraindication to anesthesia 2: Severe hepatic or renal dysfunction (e.g., elevated serum transaminases = 2.5 times the upper limit of normal values, blood creatinine level = 176.8 umol/L) 3: Severe cardiopulmonary insufficiency (e.g., heart failure or chronic obstructive pulmonary disease) 4: poorly controlled hypertension (systolic blood pressure = 160 mmHg and/or DBP = 100 mmHg on antihypertensive medication) or diabetes mellitus (glycated hemoglobin = 9%) 5: Long-term opioid users or alcoholics 6: Severe hearing, vision, intellectual disability and mental illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First induction success rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of overall adverse events;Total amount of additional drugs during the examination;Anesthesia induction time;Vital signs;Anesthesia awakening time;Pain score; | — |
Countries
China
Contacts
Public ContactNa Xing
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed